Vertex Pharmaceuticals NASDAQ: VRTX is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the pain management sector, presenting a compelling growth opportunity for the company and its investors. As the global market seeks effective, non-opioid pain treatments, Vertex's advancements in this area could solidify its leadership in developing next-generation pain solutions, substantially increasing its market va ...

It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much.However, there are exceptions. Sometimes, a stock has a potential catalyst right around the corner. In such a case, investors could be much better off buying sooner rather than later.Vertex Pharmaceuticals (VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30?A key date for VertexWhat's ...

公司动态 - Vertex Pharmaceuticals 宣布多项项目更新 包括 FDA 批准其治疗囊性纤维化的新药 ALYFTREK 适用于 6 岁及以上至少有一个 F508del 突变或对 ALYFTREK 有反应的其他 CFTR 基因突变的患者 [1] - Vertex 将主要市场的囊性纤维化患者估计数提高至 94000 人 预计报销安排将使 10000 名符合条件的患者获得治疗 [1] - Vertex 的 CASGEVY 在阿联酋获得镰状细胞病和输血依赖性β地中海贫血的监管批准 [7] - 用于中度至重度急性疼痛的 Suzetrigine 等待 FDA 在 2025 年 1 月 30 日前做出决定 处于优先审查中 [7] - 在 1 型糖尿病方面 zimislecel 进入针对 125000 名患者的 3 期试验 包括 VX-264 中的封装胰岛细胞在内的补充疗法正在推进 关键数据预计在 2025 年 [7] 行业分析 - RBC Capital Markets 表示 Vertex 管理层对最近批准的 ALYFTREK 持乐观态度 预计 6000 名停止使用其他 CFTR 调节剂的患者和许多目前正在接受现有治疗的患者将转向这种下一代疗法 [3] - RBC 分析师 Brian Abrahams 指出 在急性疼痛方面 Suzetrigine 的定价可能高于预期 公司强调不希望为了快速批准其第一种药物而冒险损害其疼痛产品组合的长期价值或慢性疼痛的成功 还指出处方集安排和付款人讨论将影响初始推出 [4] - 高盛分析师 Salveen Richter 认为 Suzetrigine 可能成为 20 多年来首个获批用于急性疼痛的非阿片类治疗药物 可以从急性和可能的慢性疼痛中产生数十亿美元的收入 如果获得批准 将为 Vertex Pharmaceuticals 提供一个重要的新收入来源 尤其是在 Casgevy 的收入在短期内仍然较低的情况下 有助于实现其商业组合的多样化 [5] 市场表现 - VRTX 股票在周二的最后一次检查中下跌 0.46% 至 411.47 美元 [6]

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, was recognized on Built In's 50 Best Remote Large Places to Work and 100 Best Remote Places to Work lists. This annual awards program recognizes companies of all sizes, from startups to enterprises, celebrating remote-first employers and those in large tech markets across the U.S. "What an incredible honor to be recognized by Built In – this award val ...

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on Built In’s 50 Best Remote Large Places to Work and 100 Best Remote Places to Work lists. This annual awards program recognizes companies of all sizes, from startups to enterprises, celebrating remote-first employers and those in large tech markets across the U.S. “What an incredible honor to be recognized by Built In – this award val ...

Vertex (VERX) shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks Internet Software industry and the S&P 500’s return of 38.1%, 40.3% and 26.8%, respectively. This strong performance highlights investor confidence in Vertex's innovative tax compliance solutions, strategic partnerships and expanding client base.Here's why adding Vertex to your portfolio makes sense now.Factors That May Benefit VertexThe increasing adoption of e-invoicing globally an ...

Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. Here's why.This growth prospect just took a heavy hitVertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). They provide the v ...

Vertex Pharmaceuticals (VRTX) announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be marketed under the brand name Alyftrek.Post the FDA’s approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator (CFTR) gene responsive to the drug. The ...

Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older, in-line with expectations, according to Goldman Sachs.Analyst Salveen Richter maintained a Buy rating for Vertex Pharmaceuticals and price target of $602.The Vertex Pharmaceuticals Thesis: During the initial launch of Alyft ...

Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.But in recent weeks, Vertex stock has declined, and last week it lost nearly 12% in one trad ...